Plans for the teams taking on rare cancers.
The same agentic in-silico engine behind every tier. Billed monthly or yearly, self-serve via Stripe, cancel anytime. A hypothesis generator and prioritisation engine, not a diagnostic.
Priced for the job done, not the seat consumed.
Two ways to buy. A researcher gets a cited ranking of candidate strata by an uncalibrated ordering signal + ranked resistance candidates + a declared proxy status per evidence layer in 180 seconds per run. A team gets drift alerts and re-runs when ClinVar or DepMap moves (in build, not yet live). An engagement gets a memo reviewed by a domain expert before delivery. What you pay for is the artefact, not the session time.
For PhD students, postdocs, junior PIs. One workspace, up to three active targets in the launch indication. Memo export, fourteen-day free trial, and weekly auto-rerun (in build, not yet live).
For a lab or a Seed-to-Series-A rare-cancer R&D team. Everything in Researcher, plus ten active targets. Multi-seat access for up to five people and shared programme memory are in build, not yet live: the workspace is single-user today, with no team or seat model behind it. Drift alerts when the evidence moves and scheduled reporting are also in build.
Cohort packs: which indication should we build next?
Every Researcher seat ships with the DMG anchor cohort. Diffuse midline glioma is the only indication live today, and its library is draft, pending DMG-expert review. The rest are on the roadmap in the order below. Curating an indication means licensing and validating a whole molecular-profile library, so it is scoped as a custom indication engagement rather than a monthly add-on. Tell us which one you need and it moves up the queue.
Diffuse midline glioma
IncludedH3 K27M anchor, n=60, DKFZ + CPTAC
Included
Ewing sarcoma
In the queueEWSR1 fusion, adolescent + young-adult anchor
Roadmap
MPNST
In the queueNF1-driven, malignant peripheral nerve sheath
Roadmap
ATRT
In the queueSMARCB1 loss, atypical teratoid rhabdoid
Roadmap
High-risk neuroblastoma
In the queueMYCN-amplified, paediatric
Roadmap
Anaplastic thyroid
In the queueBRAF V600E, TP53 co-mutation
Roadmap
Rhabdomyosarcoma
In the queuePAX-FOXO1 fusion, paediatric
Roadmap
Pediatric AML (KMT2Ar)
In the queueKMT2A-rearranged, infant + paediatric
Roadmap
A pack leaves the queue once its anchor cohort has been curated and validated end-to-end through the run pipeline. Diffuse midline glioma is the only pack live today, and its library is draft, pending DMG-expert review. Every other indication listed here is roadmap, not shipped, and ships in order.
Candidate strata ranked by an uncalibrated ordering signal, each with a descriptive 10th to 90th percentile band, the top-3 ranked resistance candidates, a declared proxy status for every evidence layer, and a citation-backed narrative. Every claim linked to a real source, every cohort frequency resampled over the real anchor n.
A live lab that will watch ClinVar, DepMap, and the literature between visits and re-run when something shifts the lead stratum's ordering signal by more than five points or drops critic agreement below 0.7. The drift calculation is written and tested. Live monitoring is being wired, so it is not running yet.
A board-ready memo reviewed by a domain expert before delivery, custom indication parameterisation curated for your specific cancer, explicit acceptance criteria agreed up front, and a follow-up analysis. The engagement, not the seat.
Patient-advocacy foundations can sponsor Researcher seats in bulk from €59 per seat / month. See the sponsorship tiers.
Billed monthly or yearly. Cancel anytime, no lock-in.
Checkout and invoicing handled by Stripe. Manage your plan from the workspace billing portal.
A hypothesis and prioritisation engine. Not a diagnostic, not a treatment recommender, not a medical device.
More on trials, billing, and commercial terms in the pricing FAQ.
Get early access to Onkydra.
We are onboarding a small group of biotech and research teams working on rare cancers. Join the waitlist and we will reach out with a first run for your programme.